<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nanobiotix S.a — News on 6ix</title>
<link>https://6ix.com/company/nanobiotix-sa</link>
<description>Latest news and press releases for Nanobiotix S.a on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nanobiotix-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683617a678dffbe2df13da0e.webp</url>
<title>Nanobiotix S.a</title>
<link>https://6ix.com/company/nanobiotix-sa</link>
</image>
<item>
<title>Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-new-preclinical-data-supporting-improved-systemic-bioavailability-and-reduced-toxicity-for-lnp-delivered-dna-immunotherapy-after-pre-treatment-with-nanoprimer-technology</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-new-preclinical-data-supporting-improved-systemic-bioavailability-and-reduced-toxicity-for-lnp-delivered-dna-immunotherapy-after-pre-treatment-with-nanoprimer-technology</guid>
<pubDate>Mon, 20 Apr 2026 04:00:00 GMT</pubDate>
<description>Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered</description>
</item>
<item>
<title>NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-provides-business-update-and-reports-full-year-2025-financial-results-6</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-provides-business-update-and-reports-full-year-2025-financial-results-6</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology</description>
</item>
<item>
<title>NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-presentation-of-first-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-presentation-of-first-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX</description>
</item>
<item>
<title>NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-to-announce-fourth-quarter-and-full-year-2025-operational-and-financial-update-on-march-31st-2026</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-to-announce-fourth-quarter-and-full-year-2025-operational-and-financial-update-on-march-31st-2026</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CESTPARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>NANOBIOTIX Statement Regarding Recent Media Speculation</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-statement-regarding-recent-media-speculation</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-statement-regarding-recent-media-speculation</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology</description>
</item>
<item>
<title>NANOBIOTIX to Participate in Investor Conferences in March</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-to-participate-in-investor-conferences-in-march</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-to-participate-in-investor-conferences-in-march</guid>
<pubDate>Wed, 25 Feb 2026 21:15:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March: TD Cowen's Health Care ConferenceDate: Wednesday, March 4, 2026Location: Boston, MATime of the fireside chat: 11:1</description>
</item>
<item>
<title>Voting Rights and Shares Capital of the Company</title>
<link>https://6ix.com/company/nanobiotix-sa/news/voting-rights-shares-capital-company-211500978</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/voting-rights-shares-capital-company-211500978</guid>
<pubDate>Tue, 13 Jan 2026 21:15:00 GMT</pubDate>
<description>In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable</description>
</item>
<item>
<title>NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-join-cac-mid-60-and-sbf-120-indices-euronext-paris-2025-12-15-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-join-cac-mid-60-and-sbf-120-indices-euronext-paris-2025-12-15-0</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical</description>
</item>
<item>
<title>Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-provides-third-quarter-2025-operational-and-financial-update-along-2026-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-provides-third-quarter-2025-operational-and-financial-update-along-2026-0</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing</description>
</item>
<item>
<title>NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-curadigm-nanoprimer-platform-advancements-updated-plans-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-curadigm-nanoprimer-platform-advancements-updated-plans-0</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary</description>
</item>
<item>
<title>NANOBIOTIX to Participate in Jefferies London Healthcare Conference</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-participate-jefferies-london-healthcare-conference-2025-11-11-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-participate-jefferies-london-healthcare-conference-2025-11-11-0</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology</description>
</item>
<item>
<title>NANOBIOTIX to Participate in Investor Conferences the Week of November 10th</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-participate-investor-conferences-week-november-10th-2025-11-03-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-participate-investor-conferences-week-november-10th-2025-11-03-0</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology</description>
</item>
<item>
<title>NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-strategic-royalty-monetization-agreement-healthcare-royalty-71-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-strategic-royalty-monetization-agreement-healthcare-royalty-71-0</guid>
<pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
<description>$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and</description>
</item>
<item>
<title>NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-updates-jnj-1900-nbtxr3-clinical-program-following-transfer-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-updates-jnj-1900-nbtxr3-clinical-program-following-transfer-0</guid>
<pubDate>Fri, 24 Oct 2025 04:00:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical</description>
</item>
<item>
<title>NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-first-data-phase-1-study-evaluating-jnj-1900-nbtxr3-patients-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-first-data-phase-1-study-evaluating-jnj-1900-nbtxr3-patients-0</guid>
<pubDate>Wed, 01 Oct 2025 04:00:00 GMT</pubDate>
<description>Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease</description>
</item>
<item>
<title>NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-provides-business-update-and-reports-half-year-2025-financial-results-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-provides-business-update-and-reports-half-year-2025-financial-results-0</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology</description>
</item>
<item>
<title>NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-updated-phase-1-results-continuing-support-jnj-1900-nbtxr3-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-updated-phase-1-results-continuing-support-jnj-1900-nbtxr3-0</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163%</description>
</item>
<item>
<title>NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-new-results-phase-1-study-evaluating-jnj-1900-nbtxr3-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-new-results-phase-1-study-evaluating-jnj-1900-nbtxr3-0</guid>
<pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
<description>Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of</description>
</item>
<item>
<title>Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-participate-hc-wainwright-27th-annual-global-investment-conference-2025-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-participate-hc-wainwright-27th-annual-global-investment-conference-2025-0</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage</description>
</item>
<item>
<title>NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)</title>
<link>https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-regulatory-harmonization-and-new-composition-matter-patent-0</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa/news/nanobiotix-announces-regulatory-harmonization-and-new-composition-matter-patent-0</guid>
<pubDate>Mon, 07 Jul 2025 04:00:00 GMT</pubDate>
<description>Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning</description>
</item>
</channel>
</rss>